Advertisement
Advertisement
U.S. markets open in 6 hours 41 minutes
Advertisement
Advertisement
Advertisement
Advertisement

IntelGenx Technologies Corp. (IGXT)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1949-0.0154 (-7.33%)
At close: 03:58PM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • H
    H
    Suboxone. What’s the status. On que to start producing in 2023 which is right around the corner.
  • G
    Guapo
    I finally got through the transcript. Thanks to those who posted links.

    In general I liked tone of the meeting. There were many good questions raised.

    The only response that concerned me was when Dr. Zerbe said, "So, I mean, it doesn’t mean necessarily that we wouldn’t raise money, but at this point, at this level, at this stock price it’s not a consideration."

    That tells me 2 things - Dr. Zerbe thinks that IGXT is currently undervalued, but they won't hesitate to dilute again if the stock price goes up. Given their good cash situation and projections for positive cash flow next year I would have preferred to have such rhetoric toned down a bit.

    Still bullish.
    Bullish
  • T
    Tim
    The US market for cannabis is anticipated to be valued at +US$40 billion by 2030, owing to growth at an exponential rate. Currently, IGXT is producing our CBD strips for Canopy and/or Aurora according to Heritage. That's a pretty good start. Once Tilray settles with us, we will be producing THC strips and patches for this burgeoning market.
  • D
    David
    royalties (sales of Rizaport, Spain only) better than doubled from $12,000 to $28,000
    At that pace that's roughly HALF A MILLION in Rizaport sales PER QUARTER by this time next year.....ALONE.
  • J
    JP
    Not if but when and how much... MJ markets opening, mainly the USA... and TLRY arb... then maybe new apps... Shroom markets opening...
    Hoping big for MONT....
  • A
    Alpha1532
    1. The CRL for the generic molecule partnered with Exeltis that was recieved in May 2022 has already been resubmitted to the FDA for review, 6 month time frame, and possible launch in Q3-4 2023 (not 2024 @BGSA).

    2. Rizaport USA resubmission within the next 3 months, Intelgenx will not be scheduling a meeting with the FDA prior to resubmission, which would expedite the process a couple months (per Dr. Zerbe).

    3. The 2 launches that would put Intelgenx in cashflow positive territory are two products mentioned above (1 & 2), and that would be in Q3-4 of 2023 (per Andre Godin).

    4. Rizaport Sales in Spain are looking good, and full year sales progress report should available to Intelgenx in October 2022, which will provide more comprehensive data (per Dr. Dana Matzen).

    5. 1/4 million CB4 Control films manufactured for Heritage to one of the top three Licensed Producers in Canada. (recent May order).

    6. VetaFilmTM-based clinical batch to our undisclosed animal health partner has been delivered, and the study results should be available in the next three months. Based on the outcome of the study, an official agreement would be possible at that time (per Dr. Dana Matzen).

    7. Manufacturing capability is 1 product per week, with a 3 week to final packaged product ready to ship. So Intelgenx's manufacturing capability is 3 different products per month.

    8. Psilocybin batches have been manufactured and delivered to Atai.

    9. Montelukast Buena study already has 22 subjects that have completed the study and final study results should be ready in Q1 2023. Increased approved dose is 30 mg twice daily. Intelgenx holds the Orange Book patent for Montelukast.

    10. Tadalafil resubmission with Aquestive in progress for Q1-2 2023.

    11. Raising funds is not a consideration at this moment, funding from Atai is already in place 3 million in Q1 2023 another by end of year pending 2 product launches (Rizaport USA and Exeltis Generic Molecule) in Q3-4 2023, which would put Intelgenx in cashflow positive territory and not require additional funding (per Mr. Andre Godin).

    12. Tilray arbitration in progress, the time frame is a lot shorter compared to a standard lawsuit through the courts. No additional comments on the progress can be disclosed at this time.\

    13. Additional 15,000 square feet being used as production storage at this time with plans for production capacity expansion in the future (per Mr. Andre Godin).

    I think this was a very good conference call over all, and it's nice to see many people participating in the Q&A. Intelgenx is progressing on many fronts simultaneously, and as was mentioned in the CC, the next to quarters will have much more PRs and updates coming through compared to this last quarter. Good luck to all Longs!!! God Bless.
    Bullish
  • D
    David
    Most significant development is our undisclosed CRL response

    Assume our undisclosed CRL response was AUG 1 as a worst case timeline (could have been 2 months ago)
    FDA has 30 days to respond
    That’s sept 1
    Acceptance is a 6 month review
    That’s MARCH 1 23 TO PRODUCTION & subsequent MARKET LAUNCH

    This is our most significant project after Montelukast and the approval and income has MORE potential than Rizaport.
    I believe so because this approval apparently bumped Rizaport batch production and also I believe the manufacturing and storage space was allocated for this ( what else could it be ?) it’s clearly a HUGE project

    And again, it’s due by March 23 at the LATEST
  • T
    TubeOne
    Conference Call Q2 Transcript Part 1
    IntelGenx Technologies Corp's (IGXT) CEO
    Horst Zerbe on Q2 2022 Results - Earnings
    Call Transcript
    Aug. 11, 2022 11:10 PM ET | IntelGenx Technologies Corp. (IGXT), IGX:CA, IGX.WT:CA SA Transcripts
    129.64K Followers
    IntelGenx Technologies Corp. (OTCQB:IGXT) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET
    Company Participants
    Stephen Kilmer – Investor Relations
    Horst Zerbe – Chief Executive Officer
    André Godin – President and Chief Financail Officer
    Dana Matzen – Vice President-Business and Corporate Development
    Tommy Kenny – Vice President-Intellectual Property, Legal Affairs and General Counsel Conference Call Participants
    Hugh Kelly – Private Investor
    Adam Tubero – Psychedelic Invest
    Lindsey Murphy – Private Investor
    Operator
    Good day everyone and welcome to today’s IntelGenx Second Quarter 2022 Financial Results Call. At this time all participants are in a listen-only mode. Later you will have an opportunity to
    ask questions during the question-and-answer session. [Operator Instructions]

    ask questions during the question-and-answer session. [Operator Instructions]
    And it is now my pleasure to turn today’s program over to Stephen Kilmer, Investor Relations.
    Stephen Kilmer
    Thank you. Good afternoon, everyone, and thank you for joining us on today’s call. With me on the line are Dr. Horst Zerbe, IntelGenx’s CEO; André Godin, our President and CFO; and Dr. Dana Matzen, the company’s Vice President of Business and Corporate Development; and Tommy Kenny, our VP, Legal Affairs and Intellectual Property and General Counsel.
    Before we begin, I would like to remind you that all amounts mentioned today are in U.S. dollars, unless otherwise mentioned, and today’s call may contain forward-looking information that represents our expectations as of today and, accordingly, are subject to change. We do not undertake any obligation to update any forward-looking statements, except as may be required by U.S. and Canadian securities laws. A number of assumptions were made by us in preparing these forward-looking statements, which are subject to risks, and results may differ materially. Details on these risks and assumptions can be found in our filings with the U.S. and Canadian securities commissions.
    I’d now like to turn the call over to Dr. Zerbe. Horst?
    Horst Zerbe
    Thank you, Steve. Good afternoon everyone and thank you for joining us for the IntelGenx second quarter 2022 conference call. On today’s call, I will provide a corporate update and discuss the progress we’ve made on our key pipeline projects. Then André will review our second quarter 2022 financial results. Following that we will open up the line for our questions. Although we continue to progress each of our development programs during the second quarter, today’s corporate update will be brief. Our material news flow, which we expect will be heavier as we enter the four months, was relatively light this quarter.
    So let me begin with ATAI. We completed the manufacturing of a clinical trial batch for one of the partner programs. The study materials will be shipped in September and we anticipate the start of the study later this year, most likely still in the third quarter. We report in May, we met with Exeltis to discuss the potential for the commercialization of RIZAPORT in additional countries.

    The call was positive with Exeltis indicating that there was a strong interest for certain Eastern European countries. In addition, we are in discussions with other distribution partners of licensing rights for [indiscernible].
    Moving on to Tadalafil, IntelGenx and Aquestive have formed a joint task force to work on the response to the CRL that Aquestive had received for the product. Now, moving on to the – to our cannabis films, we are working to fulfill Heritage’s purchase order for their resale of our CB4 Control film containing CBD to one of the top three license producers in Canada that is expected to happen in early September. Accordingly, we expect the related revenue to be reflected in our Q4 2022 results. Our partner Heritage continues to rush CBD distribution in Canada and recently got the product listing – listed on the Shoppers drug Mart website. We continue to push distribution in Canada and recently met with the Nova Scotia Liquor Corporation to discuss the products. And finally as per two-way [ph] litigation, Tommy will be available for questions during the Q&A session.
    Now moving on to montelukast and initially regarding the BUENA study, as we reported earlier in the year, the study and correspondingly our recruitment efforts have resumed. Recruitment is ongoing with six sites activated. As of now a total of 33 patients have been randomized, 22 of which have completed treatment. We’re working diligently to improve the recruitment rate and have now launched a Facebook awareness campaign to attract more study participants and accelerate enrollment.
  • J
    JP
    Concerns about dilution... it first depends a lot on arb with TLRY... that will indicate if it is needed.... The market as of today is pricing in MONT failure.... if it is successful then dilution after a market correction then perhaps... I am not expecting any further dilution assuming a q3 23 launch of USA RIZ..
  • T
    Tim
    As shareholders, we are no longer waiting on "years" to get our strips FDA approved and on market, we are now waiting "months", period. No more years, now only months. That's a hell of a statement if you've been frozen-in-time holding this company's stock for years. We all know our Rizaport EU is on-line as well as our CBD strips, but we are now only months away from what sounds like (2) FDA VersaFilm approvals, from what management tells us. Rizaport and Suboxone(?) USA launches in 2023 is a "big deal", period. I speculate by the time our Cialis strips get FDA approval in early 2024 IntelGenx will be operating profitably deep in-the-black.

    Months, not years. Say that twice, slowly, let it soak-in.

    And have a great safe weekend all~
    Bullish
  • D
    David
    Alpha … I thought I heard Q2 for launch of undisclosed
    If submitted, 6 months is Feb 23
  • A
    Alpha1532
    “Of particular note, we delivered a VetaFilmTM-based clinical batch to our undisclosed animal health partner. On the commercial front, we are working to fulfill a purchase order received in May from Heritage Cannabis for their resale of our CB4 Control film to one of the top three Licensed Producers in Canada.”
    Bullish
  • H
    H
    Tremendous volume at the open. 100 whole shares after 20 minutes.
  • T
    Tim
    IGXT produced and shipped a sample batch of our VetaFilm strips to our prospective partner. The company will now perform testing on dogs and study and analyze our strips, hopefully they work well/as promised and then hopefully a commercialization partnership follows. I believe we shipped our strips to a "large" Pet company in the USA if memory serves from past company statements.

    Andre pretty much stated we will need the extra warehouse space when a caller asked. I speculate IGXT and PAR partnered with Exeltis to produce our generic Suboxone strips. Just a hunch. I can't think of what other molecule it could be considering Horst stated it was not Buprenorphine today. He answered the caller "I don't know where you heard that" when Buprenorphine was asked about.

    Another note: +22 people have already finished our Montelukast trial? Did I hear that right? Horst did mention Emory's clinical trials were delayed by Covid, but it sounds like our enrollment is going fine? They can't discuss any data and/or antidotal info until the trials are published, I believe.

    VetaFilm sample batch produced and shipped, and MYSTERY DRUG to launch in early 2023. Is this mystery drug our generic Suboxone? Do we need a lot of warehouse space in shipping and receiving?

    Hope so. IGXT brass feel pretty confident of their cash position as well as the company turning into cash-flow-positive operations in the next Fall. January 1, 2023 is +4 months away.

    Exciting, to shareholders. In my opinion.
    Bullish
  • W
    Waxingeloquence
    easily the most questions I have seen asked on an IGXT investor call...exciting.
    Bullish
  • D
    David
    Licensing revenues more than doubled ….that means riz Europe sales doubled…
  • D
    David
    Also negotiating Riz Eastern European launch (Poland, etc….)
  • J
    Jazz
    I have to give Z some props for skipping the sit down with the FDA. It definitely hasn't helped in the past. He saved us some time and ultimately some money.
  • H
    H
    Anyone ask about Suboxone launch? Almost 2023.
Advertisement
Advertisement